-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sparsentan in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Sparsentan...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VC-01 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VC-01 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VC-01 in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-407 in Polycystic Kidney Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-407 in Polycystic Kidney Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VX-407 in Polycystic Kidney Disease Drug Details: VX-407 is under...
-
Sector Analysis
NewFuture of Pharma – Looking Ahead to 2024
This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot and prioritize them within your sectors.
-
Product Insights
NewNet Present Value Model: Vertex Pharmaceuticals Inc’s Suzetrigine
Empower your strategies with our Net Present Value Model: Vertex Pharmaceuticals Inc's Suzetrigine report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has...
-
Thematic Analysis
Rare Disease ​Pipeline Analysis ​Landscape, 2023
This report investigates the Rare Disease ​Pipeline Analysis ​Landscape in 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize these trends within your sector.
-
Product Insights
NewNet Present Value Model: Vertex Pharmaceuticals Inc’s VX-548
Empower your strategies with our Net Present Value Model: Vertex Pharmaceuticals Inc's VX-548 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-993 in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-993 in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VX-993 in Pain Drug Details: VX-993 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eflornithine in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eflornithine in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eflornithine in Glioblastoma Multiforme (GBM) Drug Details: Eflornithine is under development...